Congenital Hyperinsulinism clinical trials at University of California Health
2 research studies open to eligible people
open to eligible people ages up to 18 years
The goal of this project is to determine the role of FDOPA/PET as a pre-operative diagnostic imaging procedure for differentiating focal and diffuse forms of congenital hyperinsulinism and locating focal lesions in the pancreas to guide surgical resection.
open to eligible people ages 2 years and up
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15136 when used as add-on therapy in subjects with CHI with persistent hypoglycemia while on standard of care treatment (SoC). HM15136 will be administered once weekly in multiple doses to subjects in multiple age including pediatric to find appropriate exposure-response data.
Our lead scientists for Congenital Hyperinsulinism research studies include Erin Okawa.